p62 participates in the inhibition of NF-κB signaling and apoptosis induced by sulfasalazine in human glioma U251 cells

Su,Jing; Liu,Fei; Xia,Meihui; Xu,Ye; Li,Xiaoning; Kang,Jinsong; Li,Yulin; Sun,Liankun

doi:10.3892/or.2015.3944

p62 participates in the inhibition of NF-κB signaling and apoptosis induced by sulfasalazine in human glioma U251 cells

Authors:
- Jing Su
- Fei Liu
- Meihui Xia
- Ye Xu
- Xiaoning Li
- Jinsong Kang
- Yulin Li
- Liankun Sun
View Affiliations

Affiliations: Department of Pathophysiology, Key Laboratory of Pathophysiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, Changchun 130021, P.R. China, Department of Nursing, First Hospital, Jilin University, Changchun 130021, P.R. China, Department of Obstetrics, First Hospital, Jilin University, Changchun 130021, P.R. China, Medical Research Laboratory, Jilin Medical College, Jilin 132013, P.R. China
Published online on: May 4, 2015 https://doi.org/10.3892/or.2015.3944
Pages: 235-243

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nuclear factor-κB (NF-κB) is constitutively activated in most malignant gliomas and is involved in cancer progression and drug resistance to chemotherapy. Sulfasalazine (SAS) is a classic inhibitor of NF-κB. Apoptosis and autophagy were induced by SAS accompanied by inhibition of NF-κB signaling in U251 cells. Inhibition of autophagy by 3-MA suppressed the effects of SAS on NF-κB signaling and apoptosis in U251 cells. Multifunctional scaffold protein p62 is well known as an autophagy marker protein and provides crosstalk for important signaling pathways, including NF-κB signaling. SAS-induced decrease in the p62 protein levels may be the result of degradation through autophagy. SAS induced the inhibition of NF-κB signaling and apoptosis at least partly via a p62-dependent effect in U251 cells. Collectively, our data shed light on the link between p62 and the NF-κB signaling pathway, particularly in glioma cells. The results may facilitate the design of more effective targeted therapies for the treatment of tumors in which NF-κB signaling is altered.

View Figures

View References

1	Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S and Kumanishi T: Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg. 96:909–917. 2002. View Article : Google Scholar : PubMed/NCBI
2	Hayashi S, Yamamoto M, Ueno Y, Ikeda K, Ohshima K, Soma G and Fukushima T: Expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 and c-Myc in human astrocytomas. Neurol Med Chir (Tokyo). 41:187–195. 2001. View Article : Google Scholar
3	Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC and Sikic BI: Tumor necrosis factor-α-induced protein 3 as a putative regulator of nuclear factor-κB-mediated resistance to O₆-alkylating agents in human glioblastomas. J Clin Oncol. 24:274–287. 2006. View Article : Google Scholar
4	Lo M, Wang YZ and Gout PW: The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 215:593–602. 2008. View Article : Google Scholar : PubMed/NCBI
5	Ryan BM, Russel MG, Langholz E and Stockbrugger RW: Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol. 98:1682–1687. 2003. View Article : Google Scholar : PubMed/NCBI
6	Narang VS, Pauletti GM, Gout PW, Buckley DJ and Buckley AR: Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res. 23:4571–4579. 2003.
7	Gout PW, Simms CR and Robertson MC: In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. Anticancer Drugs. 14:21–29. 2003. View Article : Google Scholar : PubMed/NCBI
8	Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M and Bours V: Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer. 9:3722009. View Article : Google Scholar : PubMed/NCBI
9	Robe PA, Bentires-Alj M, Bonif M, Rogister B, Deprez M, Haddada H, Khac MT, Jolois O, Erkmen K, Merville MP, et al: In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res. 10:5595–5603. 2004. View Article : Google Scholar : PubMed/NCBI
10	Habens F, Srinivasan N, Oakley F, Mann DA, Ganesan A and Packham G: Novel sulfasalazine analogues with enhanced NF-κB inhibitory and apoptosis promoting activity. Apoptosis. 10:481–491. 2005. View Article : Google Scholar : PubMed/NCBI
11	Müerköster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Fölsch UR, et al: Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer. 104:469–476. 2003. View Article : Google Scholar : PubMed/NCBI
12	Ogier-Denis E and Codogno P: Autophagy: a barrier or an adaptive response to cancer. Biochim Biophys Acta. 1603:113–128. 2003.PubMed/NCBI
13	Shintani T and Klionsky DJ: Autophagy in health and disease: a double-edged sword. Science. 306:990–995. 2004. View Article : Google Scholar : PubMed/NCBI
14	Marino G and Lopez-Otin C: Autophagy: molecular mechanisms, physiological functions and relevance in human pathology. Cell Mol Life Sci. 61:1439–1454. 2004. View Article : Google Scholar : PubMed/NCBI
15	Eskelinen EL: Maturation of autophagic vacuoles in mammalian cells. Autophagy. 1:1–10. 2005. View Article : Google Scholar
16	Djavaheri-Mergny M, Amelotti M, Mathieu J, Besançon F, Bauvy C, Souquère S, Pierron G and Codogno P: NF-kappaB activation represses tumor necrosis factor-alpha-induced autophagy. J Biol Chem. 281:30373–30382. 2006. View Article : Google Scholar : PubMed/NCBI
17	Trocoli A and Djavaheri-Mergny M: The complex interplay between autophagy and NF-kappaB signaling pathways in cancer cells. Am J Cancer Res. 1:629–649. 2011.
18	Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, Lam S, Gout PW and Wang YZ: The x_c-cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol. 64:463–472. 2009. View Article : Google Scholar
19	Yu H, Su J, Xu Y, Kang J, Li H, Zhang L, Yi H, Xiang X, Liu F and Sun L: p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. Eur J Cancer. 47:1585–1594. 2011. View Article : Google Scholar : PubMed/NCBI
20	White E, Karp C, Strohecker AM, Guo Y and Mathew R: Role of autophagy in suppression of inflammation and cancer. Curr Opin Cell Biol. 22:212–217. 2010. View Article : Google Scholar : PubMed/NCBI
21	Rosenfeldt MT and Ryan KM: The multiple roles of autophagy in cancer. Carcinogenesis. 32:955–963. 2011. View Article : Google Scholar : PubMed/NCBI
22	Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT and Moscat J: The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J. 18:3044–3053. 1999. View Article : Google Scholar : PubMed/NCBI
23	Wooten MW, Seibenhener ML, Mamidipudi V, Diaz-Meco MT, Barker PA and Moscat J: The atypical protein kinase C-interacting protein p62 is a scaffold for NF-kappaB activation by nerve growth factor. J Biol Chem. 276:7709–7712. 2001. View Article : Google Scholar : PubMed/NCBI
24	Wooten MW, Geetha T, Seibenhener ML, Babu JR, Diaz-Meco MT and Moscat J: The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. J Biol Chem. 280:35625–35629. 2005. View Article : Google Scholar : PubMed/NCBI
25	Moscat J, Diaz-Meco MT and Wooten MW: Signal integration and diversification through the p62 scaffold protein. Trends Biochem Sci. 32:95–100. 2007. View Article : Google Scholar
26	Moscat J, Diaz-Meco MT, Albert A and Campuzano S: Cell signaling and function organized by PB1 domain interactions. Mol Cell. 23:631–640. 2006. View Article : Google Scholar : PubMed/NCBI
27	Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT and Moscat J: The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell. 13:343–354. 2008. View Article : Google Scholar : PubMed/NCBI
28	Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R and Spendlove I: The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer. 14:73–80. 2007. View Article : Google Scholar : PubMed/NCBI
29	Su J, Xu Y, Zhou L, Yu HM, Kang JS, Liu N, Quan CS and Sun LK: Suppression of chloride channel 3 expression facilitates sensitivity of human glioma U251 cells to cisplatin through concomitant inhibition of Akt and autophagy. Anat Rec (Hoboken). 296:595–603. 2013. View Article : Google Scholar
30	Liu N, Xu Y, Sun JT, Su J, Xiang XY, Yi HW, Zhang ZC and Sun LK: The BH3 mimetic S1 induces endoplasmic reticulum stress-associated apoptosis in cisplatin-resistant human ovarian cancer cells although it activates autophagy. Oncol Rep. 30:2677–2684. 2013.PubMed/NCBI
31	Guo W, Zhao Y, Zhang Z, Tan N, Zhao F, Ge C, Liang L, Jia D, Chen T, Yao M, et al: Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma. Cancer Lett. 312:55–61. 2011. View Article : Google Scholar : PubMed/NCBI
32	Moscat J and Diaz-Meco MT: p62 at the crossroads of autophagy, apoptosis and cancer. Cell. 137:1001–1004. 2009. View Article : Google Scholar : PubMed/NCBI
33	Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461–466. 2004. View Article : Google Scholar : PubMed/NCBI
34	Zanotto-Filho A, Braganhol E, Schröder R, De Souza LH, Dalmolin RJ, Pasquali MA, Gelain DP, Battastini AM and Moreira JC: NFkappaB inhibitors induce cell death in glioblastomas. Biochem Pharmacol. 81:412–424. 2011. View Article : Google Scholar
35	Kesanakurti D, Chetty C, Rajasekhar Maddirela D, Gujrati M and Rao JS: Essential role of cooperative NF-κB and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma. Oncogene. 32:5144–5155. 2013. View Article : Google Scholar
36	Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY and Sontheimer H: Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci. 25:7101–7110. 2005. View Article : Google Scholar : PubMed/NCBI
37	Moriuchi S, Glorioso JC, Maruno M, Izumoto S, Wolfe D, Huang S, Cohen JB and Yoshimine T: Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IkappaBalpha and HSV thymidine kinase. Cancer Gene Ther. 12:487–496. 2005.PubMed/NCBI
38	Martin P, Diaz-Meco MT and Moscat J: The signaling adapter p62 is an important mediator of T helper 2 cell function and allergic airway inflammation. EMBO J. 25:3524–3533. 2006. View Article : Google Scholar : PubMed/NCBI